Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.49 USD | +1.59% | +0.43% | -40.95% |
Financials (USD)
Sales 2024 * | 968M | Sales 2025 * | 1.1B | Capitalization | 3B |
---|---|---|---|---|---|
Net income 2024 * | 112M | Net income 2025 * | 219M | EV / Sales 2024 * | 2.47 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 863M | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
14.1
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.48% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | -0.69% | ||
1 week | -1.14% | ||
Current month | -21.69% | ||
1 month | -23.35% | ||
3 months | -42.01% | ||
6 months | -15.47% | ||
Current year | -41.87% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | -.--% | - | |
1.24% | 17 M€ | -0.46% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 18.49 | +1.59% | 1 481 512 |
24-03-27 | 18.2 | +2.30% | 1,701,367 |
24-03-26 | 17.79 | -0.28% | 1,445,409 |
24-03-25 | 17.84 | -0.61% | 1,845,162 |
24-03-22 | 17.95 | -2.50% | 1,480,951 |
Delayed Quote Nasdaq, March 28, 2024 at 10:05 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.87% | 3B | |
+8.90% | 45.97B | |
+52.62% | 43.93B | |
+9.95% | 42.34B | |
-8.59% | 28.27B | |
+17.25% | 27.18B | |
-20.27% | 19.44B | |
+14.26% | 13.83B | |
+31.67% | 12.4B | |
+8.61% | 11.45B |